Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 30, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column is published regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to follow along as we highlight milestone moments from our portfolio companies.
Corporate ESG
HyperStrong Named a Five-Star Outstanding Enterprise in China Supplier ESG Ratings
Recently, the China Supplier ESG Rating Platform unveiled the first batch of pilot ratings. Qiming Venture Partners portfolio company HyperStrong (688411.SH) was rated a five-star outstanding enterprise for its exceptional practices in environmental management, social responsibility, and corporate governance (ESG), demonstrating strong industry recognition of the company's sustainability efforts.
As a leader in the energy storage industry, HyperStrong deeply understands the strategic value of ESG principles in strengthening core capabilities, enhancing competitiveness, and driving high-quality development. In recent years, with the mission of "empowering green energy and co-creating a zero-carbon ecosystem," the company has focused on energy storage technology innovation and industrial application, accelerating breakthroughs in electrochemical energy storage system integration, intelligent operations and maintenance, and other key technologies. It has developed more efficient, lower-carbon, and more reliable energy storage solutions, providing solid support for energy transition across grid-side, power-source-side, and user-side scenarios while helping improve the security resilience and green efficiency of energy systems. At the same time, HyperStrong actively engages with industry partners to build and share a sustainable industrial ecosystem, integrating ESG principles comprehensively into strategic planning and operational processes, and steadily enhancing its capacity for sustainable value creation.
Funding News
Huimei Technology Raises RMB 200 Million in New Round; Qiming Venture Partners Continues to Invest
Recently, leading medical AI solutions provider Huimei Technology announced the completion of a nearly RMB 200 million new funding round. Qiming Venture Partners participated in this round as a follow-on investor.
Founded in 2015, Huimei Technology has remained focused on applying artificial intelligence (AI) technology to solve clinical pain points. By connecting real-time clinical data within hospitals, the company has built an AI clinical data foundation. Combined with its strong medical expertise and evidence-based medical knowledge base, it has developed three categories of solutions: AI-assisted clinical decision-making, in-process quality control, and in-process cost control, comprehensively covering the core clinical, management, and cost-control scenarios of healthcare institutions.
Dr. Zhang Qi, founder, chairman, and CEO of Huimei Technology, said: "Since 2025, we have seen tremendous enthusiasm from hospital clients for applying large-model technology to solve clinical pain points. Numerous fragmented clinical tasks that were previously difficult to productize have seen dramatically improved processing efficiency thanks to large models and intelligent agents. Over the past decade, Huimei Technology has built an AI clinical data foundation across more than 1,200 hospitals, enabling intelligent agents to seamlessly integrate with physician workflows in clinical settings and achieve true one-click activation. This is the fundamental reason behind the rapid growth of our large-model platform and business this year — you could call it 'ten years building the road, one day opening to traffic.'"
Major Partnerships
01/
China's Leading Sportswear Brand Li-Ning Partners with Shangyue to Launch Non-Production SRM System
Recently, Li-Ning (China) Sports Goods Co., Ltd. ("Li-Ning") partnered with Qiming Venture Partners portfolio company Shangyue to successfully launch a non-production SRM (Supplier Relationship Management) system project. Shangyue will leverage its advanced digital procurement solutions to help Li-Ning achieve full traceability of non-production procurement, centralized resource management, and data value extraction, comprehensively improving procurement management efficiency and compliance.
This project will establish a full-traceability system integrating business flow, approval flow, and data flow by standardizing key nodes in the procurement process. It will support real-time monitoring and tracking throughout the procurement lifecycle, enhancing management transparency and compliance. By breaking down information silos and deeply integrating procurement demand pools with supplier resource pools, the platform will center on category management to strengthen the group's centralized procurement strategy formulation and execution control capabilities. It will also systematically collect, integrate, and analyze full-lifecycle procurement data to generate multi-dimensional, visualized management insight reports, providing management with comprehensive, accurate, and timely decision-making support.
02/
CANbridge Announces Strategic Partnership with Baheal Pharmaceutical
Recently, Qiming Venture Partners portfolio company CANbridge (01228.HK) announced an expanded strategic partnership with Baheal Pharmaceutical, a leading innovative brand commercialization platform in China. Under the agreement, a subsidiary of Baheal Pharmaceutical will serve as the exclusive commercial services provider for CANbridge's specific products in mainland China, Hong Kong, and Macau, with Baheal Pharmaceutical's affiliates also having the option to serve as distributors in these markets.
Dr. Xue Qun, founder, chairman, and CEO of CANbridge, said: "We are pleased to announce this strategic partnership with Baheal Pharmaceutical. As a leading innovative brand commercialization platform in China, Baheal Pharmaceutical has extensive network resources and strong business capabilities that will help CANbridge expand and scale our commercial activities, accelerating market penetration of our already-launched products."
03/
MedSci Health Partners with Hainan International Medical Center to Build Digital Intelligence Innovation Center
Recently, Qiming Venture Partners portfolio company MedSci Health (02415.HK) reached a strategic partnership with Shanghai Jiao Tong University School of Medicine Hainan International Medical Center, and held an unveiling ceremony for the "MedSci Hainan International Medical Digital Intelligence Innovation Center."
Under the cooperation agreement, both parties will conduct strategic planning in key areas including international medical talent training and continuing education, research platform construction and data application, and commercialization of key research projects.
R&D Progress
01/
Insilico Medicine Announces Completion of NLRP3 Inhibitor
IND-Enabling Studies for ISM8969
Recently, Qiming Venture Partners portfolio company Insilico Medicine announced that its oral NLRP3 inhibitor ISM8969, targeting inflammatory and neurodegenerative diseases, has completed IND-enabling studies with positive results supporting further clinical validation. Based on existing data, Insilico Medicine plans to submit an IND application in the fourth quarter of this year, aiming to advance the candidate compound into clinical trials as a potentially transformative therapy for Parkinson's disease (PD).
In the IND-enabling studies, researchers conducted three behavioral tests — open field test, rotarod test, and grip strength test — to evaluate ISM8969's improvement of motor function in a Parkinson's disease mouse model. Data showed that mice treated with ISM8969 demonstrated a highly dose-dependent trend in motor improvement. At a 20 mpk dose, significant improvement was observed in disease-induced model mice, with corresponding metrics approaching those of healthy control groups.
02/
Insilico Medicine Uses AI Tools to Reveal Connection Between Idiopathic Pulmonary Fibrosis and Accelerated Aging
Recently, a research team from Qiming Venture Partners portfolio company Insilico Medicine published a study in the journal Aging (Aging-US), using artificial intelligence methods to investigate aging-related biological mechanisms in idiopathic pulmonary fibrosis (IPF). The study establishes a novel link between aging biology and IPF pathogenesis, while demonstrating the significant potential of AI-driven approaches in researching therapies for aging-related diseases.
To advance this research, the team developed two specialized deep learning models: the Fibrosis-aware Aging Clock, a pathway-focused proteomic aging clock trained on proteomic data from the UK Biobank; and IPF-Precious3GPT, an omics Transformer model that generates gene differential expression profiles from text prompts.
03/
VINNO Contributes to Research on Ultrasound-Excited Microbubble Cavitation Combined with Nitric Oxide Signaling Pathway Published in International Journal
Recently, research findings on ultrasound-excited microbubble cavitation combined with the nitric oxide signaling pathway were formally published in Academic Radiology, a core international academic journal sponsored by the Association of University Radiologists and published by Elsevier. In this breakthrough study, the VFlash low-intensity ultrasound therapy technology and URM super-resolution microscopy imaging technology, both equipped on the ULTIMUS 9E series ultrasound devices from Qiming Venture Partners portfolio company VINNO, formed a powerful synergy greater than the sum of its parts, providing core technical support for precise experimental implementation.
This study not only confirmed the feasibility of ultrasound combined with the nitric oxide pathway to improve tumor perfusion, but also established the "golden combination" of sodium nitrite (SN) plus ultrasound-excited microbubble cavitation (USMC) through rigorous data. For patients, this means that in the future, safer, non-invasive ultrasound technology combined with specific drugs may be used to "open up" tumor blood vessels, thereby enhancing treatment efficacy and reducing chemotherapy side effects. As technology continues to evolve, ultrasound-mediated tumor microcirculation regulation could become an important boost for improving the efficacy of radiotherapy, chemotherapy, and immunotherapy, opening new paths for solid tumor treatment.
04/
Bayprotec SISPROT Preprocessing Kit Enables Plasma Exosome Proteomics Detection
Recently, a research article was published in Aging Cell by the team of Professor Zheng Lei from the Department of Laboratory Medicine at Nanfang Hospital, Southern Medical University, and Professor Kenneth W. Witwer from the Johns Hopkins University School of Medicine. Using the SISPROT sample preprocessing kit from Qiming Venture Partners portfolio company Bayprotec, the researchers performed efficient sample preprocessing and high-depth proteomics detection on plasma exosomes and corresponding protein fractions from 120 healthy volunteers. For the first time, the study systematically revealed the differential effects of age and sex on plasma extracellular vesicles (EVs) and protein components (PROT) in healthy individuals, emphasizing the importance of demographic factors in EVs research.
By innovatively adopting SISPROT (integrated spin-tip) proteomics preprocessing technology combined with size exclusion chromatography (SEC) separation strategy, this study confirmed the advantages of the SEC-SISPROT combined technique in resolving complex plasma components: significantly improving the identification efficiency of low-abundance proteins, overcoming the interference of co-isolated contaminants from EVs that plagues traditional methods, and ensuring data reliability.
Product Launches
01/
SceneRay Officially Launches Gemini System, Leading Deep Brain Stimulation Technology into the 2.0 Era
During the 22nd Academic Conference of the Chinese Neurosurgical Society, Qiming Venture Partners portfolio company SceneRay held the "DBS 2.0 Era: Multi-Neural Circuit Combined Modulation and SceneRay Gemini System New Product Launch." At the event, SceneRay officially launched the Gemini system (SR1384Y extension lead), announcing that deep brain stimulation (DBS) technology has entered the 2.0 era and opening new exploration into multi-neural circuit combined modulation.
In his presentation "DBS 2.0 Era: Multi-Neural Circuit Combined Modulation," SceneRay Chairman Ning Yihua noted that neuroregulation technology brought Parkinson's treatment into a new phase 30 years ago, but subsequent technical improvements mostly focused on single targets and single neural circuits. However, neurological diseases often involve multi-neural circuit damage, and single-target modulation has significant limitations, such as inability to address freezing of gait, long-term tolerance, and declining efficacy. With the launch of the Gemini system, new treatment approaches are now available for multiple conditions. Combined with visualized programming, this will break through the efficacy ceiling, and SceneRay looks forward to collaborating with experts to lead DBS technology development.
02/
Two Bioscience Liquid Chromatography-Tandem Mass Spectrometry Detection Kits from Bioscience Receive Medical Device Registration Certificates
Recently, two liquid chromatography-tandem mass spectrometry (LC-MS/MS) detection kits independently developed by Qiming Venture Partners portfolio company Bioscience have officially received medical device registration certificates issued by the Chongqing Municipal Medical Products Administration.
The two approved detection kits are a steroid hormone detection kit and a total triiodothyronine (TT3) and total thyroxine (TT4) detection kit. Both employ liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology with advantages of high accuracy, high sensitivity, and high specificity, meeting the needs of clinical and research institutions for precise detection.
Corporate Development
01/
Zai Lab Establishes Oncology Scientific Advisory Board
Recently, Zai Lab (NASDAQ: ZLAB, 09688.HK), a Qiming Venture Partners portfolio company, announced the establishment of an Oncology Scientific Advisory Board (SAB). The newly formed committee comprises leading oncology experts who will support the advancement of the company's robust oncology pipeline, including multiple internally developed investigational therapies.
"We are honored to bring together this esteemed group of oncology experts who will help Zai Lab continue to develop and advance innovative treatment options for patients around the world," said Dr. Rafael G. Amado, President and Global Head of R&D at Zai Lab. "The establishment of this committee is a very important step for Zai Lab; we believe the guidance and insights provided by these highly respected and experienced experts will strongly propel our clinical programs."
02/
Berry Genomics Partners with Leading Expert to Form Joint Venture, Advancing Integrated Genetic Disease Testing for Newborns and Children
Recently, to better advance the integrated genetic disease testing service system for newborns and children, Berry Genomics (000710.SZ), a Qiming Venture Partners portfolio company, plans to establish a joint venture with Professor Li Wei in Zhengzhou, Henan Province. The partnership aims to deliver integrated genetic disease testing services for newborns and children in key regions including Henan, through close collaboration between public medical institutions and clinical healthcare enterprises.
Professor Li Wei has long been dedicated to the field of pediatric genetics. He currently serves as Professor and Doctoral Supervisor at Beijing Children's Hospital, Capital Medical University. His academic appointments include Director of the Genetic and Birth Defect Prevention and Control Center at the National Children's Medical Center, Director of the Ministry of Education Key Laboratory of Major Diseases in Children, Director of the Beijing Key Laboratory of Key Technologies for Prevention and Treatment of Emerging Infectious Diseases in Children, and Director of the Children's Medical Research Institute at Henan Academy of Medical Sciences.
This collaboration will leverage the National Children's Medical Center's leading role and R&D strengths in genetic disease screening, diagnosis, and treatment for children, combined with Berry Genomics' deep technical and service expertise, to create a model demonstration for China's three-tier prevention system for birth defects. Going forward, with the assistance of the AI agent GENOisi™, this partnership will generate innovative practices with both economic and social benefits, ultimately forming a replicable and scalable new model for regional children's health management that provides scientific assurance for millions of families.
03/
ZhenGe Biologics Advances 500L Reactor Drug Substance Production Line Project
Recently, ZhenGe Biologics, a Qiming Venture Partners portfolio company, announced that it began planning and constructing a 500L reactor drug substance production line project in January 2025. The line will meet an annual capacity of 30,000 liters, with an estimated annual output value of approximately 360 million yuan. Once the new line is operational, ZhenGe Biologics' Lingang production base will simultaneously house a 5,000L stainless steel system alongside 500L/2,000L single-use reactor systems, enabling efficient and flexible fulfillment of diverse customer needs while expanding production capacity and business scope.
The new 500L production line leverages the existing weighing and dispensing center and employs advanced single-use manufacturing processes, including cell revival, cell fermentation, and downstream purification workflows. Designed according to the latest GMP standards, it prevents cross-contamination through rational workshop layout while maintaining visitability. All critical process equipment is sourced from world-class international brands to ensure product quality and on-time delivery.
Technology Strength
01/
Multiple Qiming Venture Partners Portfolio Companies Appear at World Robot Conference 2025
Recently, the World Robot Conference 2025 (WRC), themed "Making Robots Smarter, Making Embodied Intelligence More Intelligent," was held in Beijing. Co-hosted by the Chinese Institute of Electronics and the World Robot Cooperation Organization, the conference featured over 200 global enterprises showcasing more than 1,500 exhibits, focusing on application scenario expansion, frontier technology innovation, key technology breakthroughs, new product launches, and international cooperation — collectively presenting the latest scientific achievements, application products, and solutions in the global robotics field.
Since its founding, Qiming Venture Partners has focused on investing in excellent early- and growth-stage companies driven by technological innovation. During the conference, multiple Qiming portfolio companies demonstrated their hardcore technological capabilities through core technology showcases, major new product releases, and cutting-edge insights. These companies included UBTECH (09880.HK), a leader in humanoid robots and intelligent service robots; Galaxy Universal, an innovator in embodied multimodal large-model general-purpose robots; DH-Robotics, a high-tech enterprise focused on core components for industrial intelligent manufacturing; Hesai Technology (NASDAQ: HSAI), a global leader in LiDAR R&D and manufacturing; and Yunji Technology, a company committed to building a world-leading service agent ecosystem. Additionally, the TOP 20 Most Investable Robot Companies in China and TOP 30 Most Promising Robot Companies in China rankings were announced during the conference, with Galaxy Universal, Tashi Zhihang, and Yuanling Ji ranking on the lists.
02/ UBTECH Helps "Tiangong" Robot Become First-Ever Humanoid Robot "Flying Man" in 100-Meter Sprint
At the 2025 World Humanoid Robot Games, "Tiangong," developed by the Beijing Humanoid Robot Innovation Center with UBTECH (09880.HK) — a Qiming Venture Partners portfolio company — as a founding member, claimed the first-ever "flying man" title for humanoid robots in the 100-meter dash.
Winning the 100-meter race with a time of 21.5 seconds, it was the only competitor to complete the run fully autonomously without remote human control, representing a revolutionary leap in robot "brain" technology.
In earlier competitions, "Tiangong" also secured second place in the 1,500-meter race, swept second, third, and fourth places in the 400-meter race, and took second place in the 4×100-meter relay. Across the 100-meter, 400-meter, and 1,500-meter events, "Tiangong" relied entirely on visual perception and environmental sensing, using multi-sensor fusion SLAM algorithms combined with an OCC surround-perception module to achieve real-time occupancy and semantic perception of its environment. It autonomously recognized lane dividers and maintained stable positioning within designated lanes despite interference from multiple robots running in the same direction and sharp-curvature turns. This precise environmental recognition, dynamic control, and autonomous execution capability will lay the groundwork for future robots to achieve autonomous mobile operations across multiple terrains and scenarios.
03/ Zhipu AI Releases GLM-4.5V, the World's Best-Performing Open-Source Visual Reasoning Model at 100B Scale
Recently, Zhipu AI, a Qiming Venture Partners portfolio company, released GLM-4.5V (106B total parameters, 12B activated parameters), the world's best-performing open-source visual reasoning model at the 100B scale, simultaneously open-sourcing it on ModelScope and Hugging Face. This represents another exploratory achievement by Zhipu AI on the path toward AGI.
GLM-4.5V is built on Zhipu AI's next-generation flagship text foundation model, GLM-4.5-Air, continuing the technical approach of GLM-4.1V-Thinking. It achieves state-of-the-art performance among open-source models at the same level across 41 public vision-language benchmarks, covering common tasks including image understanding, video comprehension, document parsing, and GUI Agent capabilities.
Through efficient mixed training, GLM-4.5V possesses the ability to process diverse visual content types, enabling full-scenario visual reasoning: image reasoning (scene understanding, complex multi-image analysis, location recognition), video understanding (long-video shot analysis, event recognition), GUI tasks (screen reading, icon recognition, desktop operation assistance), complex charts and long-document parsing (research report analysis, information extraction), and grounding capabilities (precise localization of visual elements). The model also adds a "thinking mode" toggle, allowing users to flexibly choose between rapid response and deep reasoning to balance efficiency and effectiveness. To help developers intuitively experience GLM-4.5V's capabilities and build their own multimodal applications, Zhipu AI has simultaneously open-sourced a desktop assistant application.
04/ Hesai Technology Ranks First in 2025 H1 China Passenger Vehicle Terminal LiDAR Installation Volume
Recently, Gasgoo Automotive Research Institute released the January–June 2025 China passenger vehicle terminal LiDAR installation ranking. The list shows that in the first half of the year, a total of 861,767 main LiDAR units were installed in the front-production mass-market segment. Among them, Qiming Venture Partners portfolio company Hesai Technology (NASDAQ: HSAI) installed 284,399 units, capturing 33.0% market share and firmly holding the top position.
Hesai Technology's ATX automotive-grade compact long-range LiDAR has gained broad market recognition for its outstanding performance, becoming a standard safety component for multiple brand models this year and penetrating into the 100,000 RMB vehicle segment, strongly empowering the launch of several hit new models.
05/ iMile Appears at One of Latin America's Largest Annual E-Commerce Events
During Fórum E-Commerce Brasil, one of Latin America's largest annual e-commerce events, Qiming Venture Partners portfolio company iMile delivered an immersive local delivery experience through its themed exhibition booth. iMile's local team built strong connections with visiting clients and logistics service providers, exploring collaboration opportunities to further expand Brazil's last-mile delivery network.
To address the consumption peak for electronics, fashion, and home goods categories in the second half of the year, iMile's Brazil team has initiated advance preparation plans covering last-mile capacity expansion, sorting center upgrades, and system capability improvements to ensure local delivery efficiency and service quality. Leveraging a logistics network covering 99% of the local population and 300 delivery outlets, the company provides clients with more flexible logistics support. iMile has further strengthened shipment forecasting and automation systems, combining real-time order data and platform traffic trends to achieve dynamic allocation of capacity and resources, providing end-to-end visibility; and ensures smooth and efficient shopping experiences through a 24/7 online local customer service team.
06/ CANbridge Pharmaceuticals' Three Rare Disease Products Pass Formulary Review for China National Healthcare Security Administration's Commercial Insurance Innovative Drug Directory
Recently, Qiming Venture Partners portfolio company CANbridge Pharmaceuticals (01228.HK) announced that three rare disease products have passed the formulary review for the China National Healthcare Security Administration's commercial insurance innovative drug directory.
The three products are: Golin® (velaglucerase alfa for injection), an enzyme replacement therapy approved in May this year for long-term treatment of patients aged 12 and above with Type I and Type III Gaucher disease; Maralixibat® (maralixibat oral solution) for the treatment of cholestatic pruritus in ALGS/PFIC; and Hensify® (idursulfase beta injection) for the treatment of Mucopolysaccharidosis Type II.
07/ Bestran Tech Unveils Major Upgrade to LabGenius S-Series Transport Robots
To address core pain points in laboratories — insufficient coverage, strict environmental constraints, repetitive and inefficient workflows, inadequate scenario flexibility, and space limitations — Qiming Venture Partners portfolio company Bestran Tech has comprehensively upgraded its LabGenius S-series transport robots with the addition of collaborative rail options, now fully compatible across the entire S-series lineup.
The collaborative rail adopts an integrated compact structural design with an aesthetically pleasing form that also offers dust-proofing and low-noise advantages, blending seamlessly into clean laboratory environments. With long-distance precise transport and high-speed operation capabilities, the collaborative rail enables seamless cross-zone flow of samples and reagents between pre-processing, testing, and storage areas, completely replacing manual relay handoffs. Through integrated design, Bestran Tech achieves a leap in operational efficiency: the collaborative rail, transport robots, and optional directional switching modules are all controlled through a single Bioyond Works® robot control software interface, consolidating three drives into one unified system for significantly improved software stability and substantially reduced deployment and maintenance costs. Equipped with collision detection and AI vision-based obstacle avoidance, the system can precisely identify surrounding instruments and laboratory personnel during high-speed operation, stopping immediately upon collision to prevent sample spillage and gripper plate drops, fundamentally eliminating safety hazards for personnel and instrument damage risks.
08/ Wushuang Medical's Cardiac Conduction System Pacing Technology Recognized by USPTO
Recently, the United States Patent and Trademark Office (USPTO) formally issued a Notice of Allowance to Qiming Venture Partners portfolio company Wushuang Medical, confirming that the patent "Catheter and Leads for Cardiac Conduction System" (Application No. 17/804,705) has passed examination, marking international authoritative recognition of Wushuang Medical's innovative achievements in cardiac conduction system pacing (CSP) technology.
Wushuang Medical's CSP pacing leads are compatible with existing defibrillators and pacemakers, support simultaneous dual-bundle branch pacing, and feature an electrode structure that more easily penetrates the ventricular septum, providing more physiological electrical signal conduction pathways and higher implantation safety, offering a superior device-based solution for heart failure treatment. This new technology will accelerate the promotion of Wushuang Medical's technology in North America and global markets, helping to advance clinical heart failure treatment levels and bring new hope to cardiovascular disease patients worldwide.
09/ Xinze Source Appears at the 2nd International Asian Veterinary Congress & Exhibition
At the 2nd International Asian Veterinary Congress & Exhibition, Qiming Venture Partners portfolio company Xinze Source made a major appearance with its comprehensive animal endoscopy solutions, demonstrating China's hardcore medical technology capabilities to the global veterinary industry.
From pet hospitals to wildlife conservation, Xinze Source provides full-chain products including high-definition endoscopy systems, minimally invasive diagnostic and treatment instruments, and disposable consumables, meeting multi-species diagnostic and treatment needs for felines, exotic pets, and equines, helping veterinarians achieve "zero-trauma" precision diagnosis. Xinze Source introduces cutting-edge technologies such as 4K ultra-high-definition imaging, 3D reconstruction, and AI-assisted diagnosis into the animal medical field, substantially reducing surgical risks and improving diagnostic and treatment efficiency, driving the Asian veterinary industry toward "precision and minimally invasive" care. Xinze Source has launched biodegradable eco-friendly consumables and equipment recycling programs, practicing corporate social responsibility while safeguarding animal health, earning high recognition from international peers.
Corporate Honors
Six Qiming Venture Partners Portfolio Company Founders Named to Wealth China's 40 Under 40 Business Elite Lists
Recently, Wealth (Chinese edition) released its China 40 Under 40 Business Elite list and China 40 Under 40 Most Promising Business Elite list. The former focuses on China's most influential young leaders of the moment, while the latter selects the most promising innovators across various industries; it is these young people who are leading changes in Chinese business and are already influencing the world.
Qiming Venture Partners portfolio companies on the lists include: JK, founder and CEO of Insta360 (688775.SH); Lixue Xia, co-founder and CEO of Infinigence AI; He Wang, founder and CTO of Galaxy Universal; and Xue Li, founder of Jieti Medical — all on the China 40 Under 40 Business Elite list. Xiang Li, founder and CEO of Shize Biotech, and Yang Wu, co-founder and CEO of moodytiger, made the China 40 Under 40 Most Promising Business Elite list.
Past Highlights
Qiming Weekly | Qiming Venture Partners Portfolio Updates Vol. 29, 2025 Qiming Stars | Multiple Qiming Venture Partners Portfolio Companies at World Robot Conference 2025
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.